ARS Pharmaceuticals (SPRY) Interest Coverage Ratio (2020 - 2026)
ARS Pharmaceuticals (SPRY) posted Interest Coverage Ratio of 1.69 for Q1 2026, up 91.09% sequentially from 18.98 in Q4 2025, and up 99.95% YoY from 0.85 in Q1 2025.
ARS Pharmaceuticals (SPRY) Interest Coverage Ratio (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Interest Coverage Ratio for 7 years, with the latest figure at 1.69 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 99.95% year-over-year to 1.69 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 5.69 (up 99.77% YoY) and the FY2025 annual result came in at 2.3, down 5224.51% from the prior year.
- Interest Coverage Ratio climbed to 1.69 in Q1 2026 per SPRY's latest filing, from 18.98 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 0.0 in Q1 2023 and troughed at 3379.73 in Q1 2025.
- A 5-year average of 238.52 and a median of 0.83 in 2022 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2023 and 2025: Interest Coverage Ratio surged 99.97% in 2023, then plunged 1986412.08% in 2025.
- Over 5 years, Interest Coverage Ratio stood at 154.43 in 2022, then jumped by 100.0% to 0.0 in 2023, then slumped by 22032750.92% to 256.51 in 2024, then surged by 92.6% to 18.98 in 2025, then soared by 91.09% to 1.69 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 1.69, 18.98, and 0.89 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | -1.75 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.75 |
| Mar 31, 2026 | -1.69 |
| Dec 31, 2025 | -18.98 |
| Sep 30, 2025 | -0.89 |
| Jun 30, 2025 | -0.27 |
| Mar 31, 2025 | -3,379.73 |
| Dec 31, 2024 | -256.51 |
| Sep 30, 2024 | -0.16 |
| Jun 30, 2024 | -0.29 |
| Mar 31, 2024 | -0.17 |
| Sep 30, 2023 | 0.00 |
| Jun 30, 2023 | 0.00 |
| Mar 31, 2023 | 0.00 |
| Dec 31, 2022 | -154.43 |
| Sep 30, 2022 | -0.78 |
| Jun 30, 2022 | -0.88 |
| Mar 31, 2022 | -1.58 |
| Dec 31, 2021 | -87.47 |
| Sep 30, 2021 | -1.04 |
| Jun 30, 2021 | -0.20 |